Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to main content

Home is Where the Heart Is: Michele Holbrook

By December 29, 2020December 4th, 2023Story of NF, SWN

In April 2020, NF patients and families received the news of a lifetime — the United States Food and Drug Administration (FDA) announced the approval of Koselugo (selumetinib). Finally, for the first time ever, there is an FDA-approved drug treatment for some patients living with NF.  Early-stage discoveries from Children’s Tumor Foundation-funded researchers proved that MEK inhibitor drugs have the potential to affect the size of NF tumors, bringing us to this moment. More than 70% of NF patients taking selumetinib in a clinical trial had shrinkage of 20 to 60% in the size of their tumors. 

While Koselugo has helped many patients living with inoperable plexiform neurofibromas, it does not help all patients living with NF. Patients like Michele Holbrook, who has schwannomatosis, and are still waiting for breakthroughs in drug development and FDA-approved treatment options. SInce first being diagnosed at age 25, Michele has had roughly eight surgeries, plus radiation, and lives with excrutiating pain every day of her life. Watch this video to hear Michele talk about living with schwannomatosis:

 

 

 

Koselugo (selumetinib) is approved only for NF1 patients with inoperable plexiform neurofibroma tumors. But the devastating effects of NF go far beyond this type of NF, and far beyond this one type of NF tumor. There is still no approved treatment option for NF patients with disfiguring cutaneous neurofibromas, life-threatening meningiomas, or painful schwannomas. We cannot stop until there are FDA-approved treatments for all forms of neurofibromatosis – NF1, NF2, and schwannomatosis.

Through the end of the year (December 31, 2020), every donation made at ctf.org/donate will be matched dollar for dollar. Help us help more NF Heroes like Michele. 

Close Menu